Chemotherapy for upper gastrointestinal tumours

Postgraduate Medical Journal

Volumn 76, Issue 896, 2000, Pages 321-327

  Thomas, A L ^a   O'Byrne, K ^a   Steward, W P ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Oesophagus; Pancreas; Stomach

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; BLEOMYCIN; CISPLATIN; CYPROTERONE ACETATE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; METHOTREXATE; MITOMYCIN; OCTREOTIDE; TAMOXIFEN; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEVER; HUMAN; LIVER CELL CARCINOMA; METASTASIS; PANCREAS CANCER; REVIEW; STOMACH CANCER;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034115182     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.76.896.321     Document Type: Review

References (36)

1. Hermanek P, Hutter RVP, Sobin LH, et al. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours. 4th Ed. Berlin: Springer-Verlag, 1997.
2. Wobst A, Audisio RA, Colleoni M, et al. Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol 1998;9: 951-62.
3. Roussel A, Bleiberg H, Dalesio O. Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial. Int J Radiat Oncol Biol Phys 1989;16:67-72.
4. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med 1992;326:1593-8.
5. Walsh TN, Noonan N, Holywood D. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
6. Anderson AP, Berdel P, Edsmyr F, et al. Irradiation, chemotherapy and surgery in esophageal cancer: a randomized clinical study. Radiother Oncol 1984;2:179-88.
7. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990;8:119-27.
8. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987;5:622-8.
9. Boyce HW. Palliation of dysphagia of esophageal cancer by endoscopic lumen restoration techniques. Cancer Control: Journal of the Moffitt Cancer Center 1999;6:73-83.
10. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
11. Coombes R, Schein P, Chilvers C, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990;8:1362-9.
12. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol 1993;11:1441-7.
13. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: a five year follow-up. Lancet 1994;343:1309-12.
14. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733-8.
15. Kang YK, Choi DW, Im Y-H, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proceedings of the American Society of Clinical Oncology 1996; 15:215.
16. Yonemura Y, Sawa T, Kinoshita K. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-62.
17. Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th Ed. Philadelphia: Lippincott-Raven, 1997: 1021-54.
18. Wils O, Klein HO, Wagener DJT. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Co-operative Group. J Clin Oncol 1991;9:827-31.
19. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
20. Lacko APJW, Langley RE, Thomas A, et al. CEF chemotherapy for advanced gastro-oesophageal cancer. Eur J Cancer 1997;33(S8):1272.
21. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann Surg 1997; 225:621-36.
22. Moertel CG, Childs DS, Reitermeier RJ. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable cancer. Lancet 1969;ii:865-7.
23. Gastrointestinal Tumour Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205-8.
24. Klaasen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-8.
25. Mallinson CN, Rake MO, Cockling JB, et al. Chemotherapy in pancreatic cancer: results of a controlled prospective, randomised, multicentre trial. BMJ 1980;281:1589-91.
26. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5.
27. Rougier P, Zarba JJ, Ducreux M. Phase II study of cisplatin and 120 hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-6.
28. Rougier P, Ducreux M, Douillard JY, et al. Efficacy of 5FU+cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): a randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG). Proceedings of the American Society of Clinical Oncology 1999;18:1050
29. Taylor OM, Benson EA, McMahon MJ, Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg 1993;80:384-6.
30. Greenway BA. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double-blind, placebo controlled trial. BMJ 1998;316: 1935-8.
31. Pazdur R Meropol NJ, Casper ES, et al. Phase II trial of ZD1694 (Tomudex (TM)) in patients with advanced pancreatic cancer. Investigational New Drugs 1996;13:355-8.
32. Abbruzzese JL, Evans D, Markowitz A. Docetaxel, a potentially active agent for patients with pancreatic adenocarcinoma. Proceedings of the American Society of Clinical Oncology 1995;14:221.
33. Casper ES, Green MR, Kelsen DP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investigational New Drugs 1994;12:29-34.
34. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
35. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
36. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treatment Reviews 1988;15:1-31.